



### **HOW TO GET MEDS**

Aaron Skiles, DNP, CFNP
UNM Sandoval Regional Medical Center/UNM HCV Elimination Project/Project ECHO

November 25, 2020

Presentation prepared by: Aaron Skiles, DNP


Date prepared: 6-11-2020

# **Objectives**

Discuss process of acquiring meds after ECHO medication recommendations



### **Medication Barriers**



## **Uniform Checklist**

#### Uniform New Mexico HCV Checklist for Centennial Care Revision Date 12/15/2017

with	GNOSIS: Chronic Hepatitis C Infection, Genotype Subtype (if applicable) (attach results), HCV RNA Level				
	nin the past 6 months: Level: Date:				
ADI	DITIONAL REQUIRED LABS (within 3 months of request- please attach results)				
	AST, ALT, Bilirubin, Albumin, INR, Platelet count, Hemoglobin, Creatinine.  document HBsAg, anti-HBs, anti-HBc				
	ER ASSESSMENT: There are seven stages of liver changes in chronic HCV infection – no liver fibrosis (F0), increasing levels brotic change (F1, F2 and F3), cirrhosis (F4), decompensated cirrhosis and hepatocellular carcinoma.				
a. FIBROSHS (HIPSOSH) / SEESMENT HOS CHARTE CHARTE CHARTE CHARTE CHARTES OF C					
Indirect markers: m-new-mexico-hcv-checklist-for-centennial-  APRI care-revision-date-12-15-2017.pdf					
	Imaging Study: Method Used: Attach results				
<ul> <li>b. Does the patient have history, physical exam, laboratory, or radiographic imaging consistent with decompensated cirr (i.e. ascites, encephalopathy, bleeding varices, etc.)?</li> <li>No Yes (attach relevant results and notes)</li> </ul>					
	<b>Child-Pugh Score (circle one):</b> Class A (CTP 5-6) B (CTP 7-9) C (CTP 10-15) See table on page 2 for calculation method If patient has decompensated liver disease (Child-Pugh B or C), it is recommended that treatment be co-managed with a gastroenterologist, infectious disease specialist or hepatologist, and that referral for transplant be strongly considered.				
	If patient has decompensated liver disease (Child-Pugh B or C), it is recommended that treatment be co-managed with a				
LIVI	If patient has decompensated liver disease (Child-Pugh B or C), it is recommended that treatment be co-managed with a gastroenterologist, infectious disease specialist or hepatologist, and that referral for transplant be strongly considered.				
<u> </u>	LIVI of fi				




# **Uniform Checklist**

	b.	b. Did patient complete treatment regimen(s)? Unknown Ves No If "No," reason for discontinuation					
	IJ.	b. Did patient complete treatment regiments): Onthown res no n	110, 1030111010				
	c. What was patient's response to therapy?  Unknown Relapse (post treatment SVR, then elevated HCV RNA level some time later)  Non-response (HCV RNA remained detectable after complete treatment course)						
d. Have you reviewed the case with Project ECHO? Yes 🔲 No 🔲 If no, health plan may require Project ECHO consulta							
6.		IESISTANCE TESTING (please attach results, if applicable) IOGO patient have genotype 1a and Zepatier will be prescribed?  NO Yes I If yes, order NS5A					
7.	RE	EQUESTED MEDICATION(S)					
Dr	ıg:_	g: Dose:	_ Duration:	weeks			
Dr	ıg:_	g: Dose:	_ Duration:	weeks			
	on current AASLD/IDSA						
		Comments:		· · ·			
	_	TE: If you are submitting a request for treatment that is not recommended in the porting medical literature.	ne AASLD/IDSA gui	dance, please submit			
8.	AD	ADHERENCE POTENTIAL $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	le of full adheren	ce to the above treatmen			
		SEE ADDITIONAL RECOMMENDATIONS O	N PAGE 2				



# CoverMyMeds (prior-authorization)





# CoverMyMeds

#### **Find Your Medication**


Testosterone

CoverMyMeds provides forms to users of this service regardless of drug, brand, plan or other relationship (busine questions, please contact us.



# CoverMyMeds

## covermymeds\*





## **Approval Letter**



P.O. Box 27489, Albuquerque, NM 87125-7489 www.phs.org

05/05/2020

Aaron Skiles 3001 BROADMOOR BLVD NE FL 3 RIO RANCHO NM 87144

Subject: Prescription Drug Request

Patients
Member Number:
Group Number:
Date of Birth: 10191563
Authorization #: 139336661

Dear

This letter is to let you know that we have approved the drug that you or your provider requested: MAVYRET 100-40 MG TABLET.

The approval is for date(s) of service: 05/05/2020 through 06/30/2020.

Mavyret 100-40 MG Tablets, 168 tablets for 56 days.


A condition of this approval is that you must fill your prescription for this drug at Presbyterian Specialty Pharmacy. You may contact the pharmacy by phone at 505-823-8800 or 1-855-775-7737 or by fax at 866-248-0801.

Formulary coverage of this medication can change. Refer to your Presbyterian Centennial Care Member Handbook for more information on prescription drug coverage. You must be eligible for coverage at the time you receive these services.
















## Questions?

#### Resources:

https://www.covermymeds.com

